Phase 2 Trial of INM-755, Cannabinol Cream for EB, Opening Soon

Phase 2 Trial of INM-755, Cannabinol Cream for EB, Opening Soon

307938

Phase 2 Trial of INM-755, Cannabinol Cream for EB, Opening Soon

A Phase 2 trial into the safety and early efficacy of INM-755, a cannabinol cream for people with epidermolysis bullosa (EB), will soon begin enrolling patients across Europe and Israel. “The start of this Phase 2 clinical trial represents a very important step forward to test the efficacy of INM-755 (cannabinol) cream in treating epidermolysis bullosa, a disease that has very few treatment options,” Alexandra Mancini, senior vice president of clinical and regulatory affairs at InMed Pharmaceuticals,…

You must be logged in to read/download the full post.